Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

@article{Fayad2011SafetyAE,
  title={Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.},
  author={Zahi A. Fayad and Venkatesh Mani and Mark Woodward and David G Kallend and Markus Abt and Tracy Burgess and Valentin Fuster and Christie M. Ballantyne and Evan A. Stein and Jean-Claude Tardif and James H F Rudd and Michael E. Farkouh and Ahmed Tawakol},
  journal={Lancet},
  year={2011},
  volume={378 9802},
  pages={1547-59}
}
BACKGROUND Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE is the first multicentre study using novel non-invasive multimodality imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints. METHODS In this phase 2b, double-blind… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 174 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 69 references

Effi cacy and safety of more intensive lowering of LDL cholesterol : a meta - analysis of data from 170 000 participants in 26 randomised trials

  • MJ Chapman, W LeGoff, M Guerin, A Kontush
  • Lancet
  • 2010

Similar Papers

Loading similar papers…